Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	DEC 01	ChemPort single article sales feature unavailable
NEWS 3	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 4	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 5	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS 6	FEB 10	COMPENDEX reloaded and enhanced
NEWS 7	FEB 11	WTEXTILES reloaded and enhanced
NEWS 8	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS 9	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS 10	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS 11	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS 12	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS 13	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS 14	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS 15	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS 16	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS 17	MAR 11	ESBIOBASE reloaded and enhanced
NEWS 18	MAR 20	CAS databases on STN enhanced with new super role for nanomaterial substances
NEWS 19	MAR 23	CA/CAplus enhanced with more than 250,000 patent equivalents from China
NEWS 20	MAR 30	IMSPATENTS reloaded and enhanced
NEWS 21	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS 22	APR 07	STN is raising the limits on saved answers
NEWS 23	APR 24	CA/CAplus now has more comprehensive patent assignee information
NEWS 24	APR 26	USPATFULL and USPAT2 enhanced with patent assignment/reassignment information
NEWS 25	APR 28	CAS patent authority coverage expanded
NEWS 26	APR 28	ENCOMPLIT/ENCOMPLIT2 search fields enhanced
NEWS 27	APR 28	Limits doubled for structure searching in CAS REGISTRY
NEWS 28	MAY 08	STN Express, Version 8.4, now available
NEWS 29	MAY 11	STN on the Web enhanced

```
 NEWS 30  MAY 11  BEILSTEIN substance information now available on
                  STN Easy
 NEWS 31  MAY 14  DGENE, PCTGEN and USGENE enhanced with increased
                  limits for exact sequence match searches and
                  introduction of free HIT display format
 NEWS 32  MAY 15  INPADOCDB and INPAFAMDB enhanced with Chinese legal
                  status data
 NEWS 33  MAY 28  CAS databases on STN enhanced with NANO super role in
                  records back to 1992

 NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
              AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:01:38 ON 29 MAY 2009

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.22       0.22

FILE 'REGISTRY' ENTERED AT 12:01:55 ON 29 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   27 MAY 2009  HIGHEST RN 1149812-77-0
DICTIONARY FILE UPDATES:  27 MAY 2009  HIGHEST RN 1149812-77-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\QUERIES\10576761.str
```





chain nodes :
18 19 21
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
chain bonds :
7-19 18-19 18-21
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-11 7-8 8-9 9-10 9-12 10-11 10-15 12-13
13-14 14-15
exact/norm bonds :
5-7 6-11 7-8 7-19 8-9 10-11 18-19 18-21
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-12 10-15 12-13 13-14 14-15
isolated ring systems :
containing 1 :

G1:C,O

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 18:CLASS 19:CLASS
21:CLASS
Generic attributes :

18:
Number of Carbon Atoms : 7 or more
Number of Hetero Atoms : 2 or more
Type of Ring System   : Polycyclic

Element Count :
Node 18: Limited
    N,N2
    O,O0
    S,S0
    C,C7

L1   STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1   STR



G1 C,O

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 12:02:12 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   3218 TO ITERATE

 62.2% PROCESSED   2000 ITERATIONS   50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 60958 TO   67762
PROJECTED ANSWERS: 15303 TO   18807

L2   50 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 12:02:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   63832 TO ITERATE

100.0% PROCESSED   63832 ITERATIONS   16703 ANSWERS
SEARCH TIME: 00.00.01

L3   16703 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\QUERIES\10576761.str





chain nodes :
18 19 21
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
chain bonds :
7-19 18-19 18-21
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-11 7-8 8-9 9-10 9-12 10-11 10-15 12-13
13-14 14-15
exact/norm bonds :
5-7 6-11 7-8 7-19 8-9 10-11 18-19 18-21
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-12 10-15 12-13 13-14 14-15
isolated ring systems :
containing 1 :

G1:C,O

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 18:CLASS 19:CLASS
21:CLASS
Generic attributes :
18:
Number of Carbon Atoms : 7 or more
Number of Hetero Atoms : 2 or more
Type of Ring System   : Polycyclic

Element Count :
Node 18: Limited
    N,N2
    O,O0
    S,S0
    C,C7

L4   STRUCTURE UPLOADED

=> d
L4 HAS NO ANSWERS
L4   STR



G1 C,O

Structure attributes must be viewed using STN Express query preparation.

=> s l4 subset=l3 full

FULL SUBSET SEARCH INITIATED 12:04:27 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 14500 TO ITERATE

100.0% PROCESSED 14500 ITERATIONS 146 ANSWERS
SEARCH TIME: 00.00.01

L5 146 SEA SUB=L3 SSS FUL L4

=>
Uploading C:\Program Files\Stnexp\Queries\QUERIES\10576761.str





chain nodes :
18 19 21
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
chain bonds :
7-19 18-19 18-21
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-11 7-8 8-9 9-10 9-12 10-11 10-15 12-13
13-14 14-15
exact/norm bonds :
5-7 6-11 7-8 7-19 8-9 10-11 18-19 18-21
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-12 10-15 12-13 13-14 14-15
isolated ring systems :
containing 1 :

G1:C,O

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 18:CLASS 19:CLASS
21:CLASS
Generic attributes :
18:
Number of Carbon Atoms : 7 or more
Number of Hetero Atoms : 2 or more
Type of Ring System   : Polycyclic

Element Count :
Node 18: Limited
    N,N2
    O,O0
    S,S0
    C,C7

L6   STRUCTURE UPLOADED

=> d
L6 HAS NO ANSWERS
L6   STR



G1 C,O

Structure attributes must be viewed using STN Express query preparation.

```
=> d his

     (FILE 'HOME' ENTERED AT 12:01:38 ON 29 MAY 2009)

     FILE 'REGISTRY' ENTERED AT 12:01:55 ON 29 MAY 2009
L1             STRUCTURE UPLOADED
L2              50 S L1
L3           16703 S L1 FULL
L4             STRUCTURE UPLOADED
L5             146 S L4 FULL SUB=L3
L6             STRUCTURE UPLOADED

=> s l6 subset=l3 full
FULL SUBSET SEARCH INITIATED 12:05:10 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -    14500 TO ITERATE

100.0% PROCESSED    14500 ITERATIONS                                 0 ANSWERS
SEARCH TIME: 00.00.01

L7              0 SEA SUB=L3 SSS FUL L6

=> s l5 and caplus/lc
      66484516 CAPLUS/LC
L8          129 L5 AND CAPLUS/LC

=> s l5 not l8
L9           17 L5 NOT L8

=> d l9 1-17
```

L9 ANSWER 1 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 1027502-87-9 REGISTRY
ED Entered STN: 12 Jun 2008
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)
MF C29 H28 F2 N4 O
SR Other Sources
Database: ChemSpider (ChemZoo, Inc.)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 ANSWER 2 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 1027155-70-9 REGISTRY
ED Entered STN: 11 Jun 2008
CN 2H-Benzimidazol-2-one, 6-[(Z)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H25 F2 N3 O3
SR Other Sources
Database: ChemSpider (ChemZoo, Inc.)

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 ANSWER 3 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 1027048-35-6 REGISTRY
ED Entered STN: 10 Jun 2008
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H26 F2 N4 O2
SR Other Sources
Database: ChemSpider (ChemZoo, Inc.)

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 ANSWER 4 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 1026946-78-0 REGISTRY
ED Entered STN: 10 Jun 2008
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-[2-[(2S,6R)-2,6-dimethyl-4-morpholinyl]ethyl]-1,3-dihydro- (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H29 F2 N3 O3
SR Other Sources
Database: ChemSpider (ChemZoo, Inc.)

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 ANSWER 5 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 1026047-11-9 REGISTRY
ED Entered STN: 06 Jun 2008
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(1R)-1-methyl-2-(1-piperazinyl)ethyl]-(CA INDEX NAME)
FS STEREOSEARCH
MF C29 H28 F2 N4 O2
SR Other Sources
Database: ChemSpider (ChemZoo, Inc.)

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 ANSWER 6 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 860115-45-3 REGISTRY
ED Entered STN: 15 Aug 2005
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(3R)-3-pyrrolidinyl- (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H21 F2 N3 O2
CI COM
SR CA

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 ANSWER 7 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 860115-44-2 REGISTRY
ED Entered STN: 15 Aug 2005
CN 2H-Benzimidazol-2-one, 1-(3-azetidinyl)-5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H19 F2 N3 O2
CI COM
SR CA

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 ANSWER 8 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 860115-43-1 REGISTRY
ED Entered STN: 15 Aug 2005
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(4-piperidinyl)- (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H23 F2 N3 O2
CI COM
SR CA

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 ANSWER 9 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 860115-42-0 REGISTRY
ED Entered STN: 15 Aug 2005
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(2R)-2-pyrrolidinylmethyl]- (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H24 F N3 O2
CI COM
SR CA

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 ANSWER 10 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 860115-41-9 REGISTRY
ED Entered STN: 15 Aug 2005
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(2S)-2-pyrrolidinylmethyl]- (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H24 F N3 O2
CI COM
SR CA

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 ANSWER 11 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 860115-40-8 REGISTRY
ED Entered STN: 15 Aug 2005
CN 2H-Benzimidazol-2-one, 1-(3-azetidinyl)-5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H20 F N3 O2
CI COM
SR CA

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 ANSWER 12 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 860115-39-5 REGISTRY
ED Entered STN: 15 Aug 2005
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(3-pyrrolidinyl)- (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H22 F N3 O2
CI COM
SR CA

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 ANSWER 13 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 860115-38-4 REGISTRY
ED Entered STN: 15 Aug 2005
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(4-piperidinyl)- (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H24 F N3 O2
CI COM
SR CA

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 ANSWER 14 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 860115-37-3 REGISTRY
ED Entered STN: 15 Aug 2005
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(3S)-3-pyrrolidinyl- (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H22 F N3 O2
CI COM
SR CA

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 ANSWER 15 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 860010-51-1 REGISTRY
ED Entered STN: 12 Aug 2005
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-[(3R)-1-ethyl-3-pyrrolidinyl]-1,3-dihydro- (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H25 F2 N3 O2
CI COM
SR CA

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 ANSWER 16 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 860010-49-7 REGISTRY
ED Entered STN: 12 Aug 2005
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(3S)-1-methyl-3-pyrrolidinyl]- (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H23 F2 N3 O2
CI COM
SR CA

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 ANSWER 17 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 860010-47-5 REGISTRY
ED Entered STN: 12 Aug 2005
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-[(3S)-1-ethyl-3-pyrrolidinyl]-1,3-dihydro- (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H25 F2 N3 O2
CI COM
SR CA

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

```
=> fil caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   320.80     321.02

FILE 'CAPLUS' ENTERED AT 12:10:44 ON 29 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 29 May 2009  VOL 150 ISS 23
FILE LAST UPDATED: 28 May 2009  (20090528/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Feb 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Feb 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate

=> d his

     (FILE 'HOME' ENTERED AT 12:01:38 ON 29 MAY 2009)

     FILE 'REGISTRY' ENTERED AT 12:01:55 ON 29 MAY 2009
L1             STRUCTURE UPLOADED
L2          50 S L1
L3       16703 S L1 FULL
L4             STRUCTURE UPLOADED
L5         146 S L4 FULL SUB=L3
L6             STRUCTURE UPLOADED
L7           0 S L6 FULL SUB=L3
L8         129 S L5 AND CAPLUS/LC
L9          17 S L5 NOT L8

     FILE 'CAPLUS' ENTERED AT 12:10:44 ON 29 MAY 2009

=> s l8
L10         7 L8

=> d ibib abs hitstr 1-7
```

L10 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:638871 CAPLUS
DOCUMENT NUMBER: 143:153374
TITLE: Preparation of tricyclic steroid hormone nuclear receptor modulators
INVENTOR(S): Gavardinas, Konstantinos; Green, Jonathan Edward; Jadhav, Prabhakar Kondaji; Matthews, Donald P.
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005066161	A1	20050721	WO 2004-US38233	20041208
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004312293	A1	20050721	AU 2004-312293	20041208
CA 2549053	A1	20050721	CA 2004-2549053	20041208
EP 1697350	A1	20060906	EP 2004-811084	20041208
EP 1697350	B1	20080625		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1918151	A	20070221	CN 2004-80041853	20041208
BR 2004016882	A	20070227	BR 2004-16882	20041208
JP 2007515431	T	20070614	JP 2006-545655	20041208
AT 399163	T	20080715	AT 2004-811084	20041208
ES 2308296	T3	20081201	ES 2004-811084	20041208
US 20070037788	A1	20070215	US 2006-576761	20060421
MX 2006007055	A	20070130	MX 2006-7055	20060619
IN 2006DN03757	A	20070622	IN 2006-DN3757	20060629
NO 2006003329	A	20060914	NO 2006-3329	20060718

PRIORITY APPLN. INFO.: US 2003-531283P P 20031219
WO 2004-US38233 W 20041208

OTHER SOURCE(S): CASREACT 143:153374; MARPAT 143:153374
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [Y = CH2, O; R1-2 = H, F; R3 = Z-amino, Z-heterocyclyl; Z = divalent alkyl; with some specific exceptions] are prepared For instance,
II is prepared from (E)-11-bromomethylene-3-fluoro-6,11-dihydrodibenzo[b,e]oxepine (prepn. given) and 1-(1,1-dimethyl-2-(morpholin-4-yl)ethyl)-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1,3-dihydrobenzimidazol-2-one (prepn. given) (dioxane, Na2CO3, [Ph3P]4Pd, 90-100°, 5 days). II has Ki ≤ 500 nM for the mineralocorticoid receptor and Ki ≤ 1,000 nM for the glucocorticoid receptor. I are useful for the treatment of congestive heart disease, hypertension, rheumatoid arthritis or inflammation.

IT 710344-06-2P 860009-94-5P 860009-95-6P
860009-96-7P 860009-97-8P 860009-98-9P
860009-99-0P 860010-00-0P 860010-01-1P
860010-02-2P 860010-03-3P 860010-04-4P
860010-05-5P 860010-06-6P 860010-07-7P
860010-08-8P 860010-09-9P 860010-10-2P
860010-11-3P 860010-12-4P 860010-13-5P
860010-14-6P 860010-15-7P 860010-16-8P
860010-17-9P 860010-19-1P 860010-21-5P
860010-23-7P 860010-25-9P 860010-26-0P
860010-27-1P 860010-28-2P 860010-29-3P
860010-30-6P 860010-32-8P 860010-34-0P
860010-36-2P 860010-38-4P 860010-40-8P
860010-42-0P 860010-44-2P 860010-45-3P
860010-46-4P 860010-48-6P 860010-50-0P
860010-52-2P 860010-53-3P 860010-54-4P
860010-55-5P 860010-56-6P 860010-57-7P
860010-58-8P 860010-59-9P 860010-60-2P
860010-61-3P 860010-62-4P 860010-63-5P
860010-64-6P 860010-65-7P 860010-66-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzimidazolone-substituted tricyclic steroid hormone nuclear receptor modulators)

RN 710344-06-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)



RN 860009-94-5 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1,1-dimethyl-2-(4-morpholinyl)ethyl]-5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 860009-95-6 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(1-methyl-4-piperidinyl)- (CA INDEX NAME)

Double bond geometry as shown.



RN 860009-96-7 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(1-methyl-4-piperidinyl)- (CA INDEX NAME)

Double bond geometry as shown.



RN 860009-97-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(1-methyl-4-piperidinyl)- (CA INDEX NAME)

Double bond geometry as shown.



RN 860009-98-9 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-[(3R)-1-ethyl-3-pyrrolidinyl]-1,3-dihydro- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860009-99-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[2-(dimethylamino)ethyl]-5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-00-0 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-01-1 CAPLUS

RN 860010-02-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-02-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(3S)-3-pyrrolidinyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 860010-03-3 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(1R)-1-methyl-2-(4-morpholinyl)ethyl]- (CA
INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860010-04-4 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(1S)-1-methyl-2-(4-morpholinyl)ethyl]- (CA
INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860010-05-5 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(4-piperidinyl)-, hydrochloride (1:1) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 860010-06-6 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[2-[(2S,6R)-2,6-dimethyl-4-morpholinyl]ethyl]-5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860010-07-7 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-08-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(3-pyrrolidinyl)-, hydrochloride (1:1) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 860010-09-9 CAPLUS
CN 2H-Benzimidazol-2-one, 1-(3-azetidinyl)-5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-, hydrochloride (1:1) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 860010-10-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(2S)-2-pyrrolidinylmethyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 860010-11-3 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(2R)-2-pyrrolidinylmethyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 860010-12-4 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-13-5 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-14-6 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(1R)-1-methyl-2-(4-morpholinyl)ethyl]-(CA
INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860010-15-7 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(1S)-1-methyl-2-(4-morpholinyl)ethyl]-(CA
INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860010-16-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-[1,1-dimethyl-2-(4-morpholinyl)ethyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-17-9 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-[2-[(2S,6R)-2,6-dimethyl-4-morpholinyl]-1,1-dimethylethyl]-1,3-dihydro- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860010-23-7 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(4-piperidinyl)-, hydrochloride (1:1) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 860010-25-9 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(3S)-3-pyrrolidinyl- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860010-19-1 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-21-5 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-26-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1-(3-azetidinyl)-5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-, hydrochloride (1:1) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 860010-27-1 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(3R)-3-pyrrolidinyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 860010-28-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(3S)-1-methyl-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860010-29-3 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-[(3S)-1-ethyl-3-pyrrolidinyl]-1,3-dihydro- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860010-34-0 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(4-piperidinyl)- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-36-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(3S)-3-pyrrolidinyl- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860010-30-6 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-32-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-38-4 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(1R)-1-methyl-2-(4-morpholinyl)ethyl]- (CA
INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860010-40-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(1S)-1-methyl-2-(4-morpholinyl)ethyl]- (CA
INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860010-42-0 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-[1,1-dimethyl-2-(4-morpholinyl)ethyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-44-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-[2-[(2S,6R)-2,6-dimethyl-4-morpholinyl]ethyl]-1,3-dihydro- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860010-48-6 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-[(3S)-1-ethyl-3-pyrrolidinyl]-1,3-dihydro-, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 860010-47-5
CMF C28 H25 F2 N3 O2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 64-19-7
CMF C2 H4 O2

RN 860010-50-0 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-



RN 860010-45-3 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-46-4 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[3-(1-piperazinyl)propyl]- (CA INDEX NAME)

Double bond geometry as shown.

ylidene)methyl]-1,3-dihydro-1-[(3S)-1-methyl-3-pyrrolidinyl]-, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 860010-49-7
CMF C27 H23 F2 N3 O2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 64-19-7
CMF C2 H4 O2

RN 860010-52-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-[(3R)-1-ethyl-3-pyrrolidinyl]-1,3-dihydro-, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 860010-51-1
CMF C28 H25 F2 N3 O2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 64-19-7
CMF C2 H4 O2

RN 860010-53-3 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(3R)-1-methyl-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860010-54-4 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-[3-(1-piperazinyl)propyl]- (CA INDEX NAME)



RN 860010-58-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-[(3S)-1-methyl-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 860010-59-9 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1-[(3S)-1-ethyl-3-pyrrolidinyl]-1,3-dihydro- (CA INDEX NAME)

Absolute stereochemistry.



RN 860010-60-2 CAPLUS



RN 860010-55-5 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 860010-56-6 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1-[2-(dimethylamino)ethyl]-1,3-dihydro- (CA INDEX NAME)



RN 860010-57-7 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)

CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-(1-ethyl-4-piperidinyl)-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-61-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1-(1-ethyl-4-piperidinyl)-5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-62-4 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-(1-ethyl-4-piperidinyl)-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.

L10 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 860010-63-5 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1-(1-ethyl-4-piperidinyl)-1,3-dihydro- (CA INDEX NAME)



RN 860010-64-6 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(4-piperidinyl)-, hydrochloride (1:1) (CA INDEX NAME)

Double bond geometry as shown.

L10 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L10 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 860010-65-7 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[(3R)-1-ethyl-3-pyrrolidinyl]-5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860010-66-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(3R)-1-methyl-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L10 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:515475 CAPLUS
DOCUMENT NUMBER: 141:71360
TITLE: Preparation of derivatives of and analogs of dibenzosuberone for use in pharmaceutical compositions as steroid hormone nuclear receptor modulators
INVENTOR(S): Coghlan, Michael Joseph; Green, Jonathan Edward; Grese, Timothy Alan; Jadhav, Prabhakar Kondaji; Matthews, Donald Paul; Steinberg, Mitchell Irvin; Fales, Kevin Robert; Bell, Michael Gregory
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 457 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004052847	A2	20040624	WO 2003-US16213	20030613
WO 2004052847	A3	20040910		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2489276	A1	20040624	CA 2003-2489276	20030613
AU 2003302220	A1	20040630	AU 2003-302220	20030613
AU 2003302220	B2	20090326		
BR 2003012095	A	20050329	BR 2003-12095	20030613
EP 1519915	A2	20050406	EP 2003-810038	20030613
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1665780	A	20050907	CN 2003-815098	20030613
CN 1331848	C	20070815		
JP 2005539088	T	20051222	JP 2004-559025	20030613
CN 101161641	A	20080416	CN 2007-10112172	20030613
US 20060063759	A1	20060323	US 2004-517010	20041203
US 7411072	B2	20080812		
IN 2004KN01910	A	20070126	IN 2004-KN1910	20041213
MX 2004012998	A	20050516	MX 2004-12998	20041217
ZA 2004010293	A	20060222	ZA 2004-10293	20041221
NO 2005000397	A	20050304	NO 2005-397	20050125

PRIORITY APPLN. INFO.:		US 2002-391992P	P 20020626
		CN 2003-815098	A3 20030613
		WO 2003-US16213	W 20030613

OTHER SOURCE(S): MARPAT 141:71360
GI



I



II

AB Dibenzosuberone derivs., such as I [X = CH2; R, R1 = H, OH, CN, halogen, alkoxy, sulfonylamino, amino, etc.; R2 = aryl, heteroaryl; R3 = H, alkyl], and heterocyclic analogs thereof, such as I [X = O, S, NH, NMe, etc.], were prepared for therapeutic use in the treatment of pathol. disorders susceptible to steroid hormone nuclear receptor modulation. These compds. are claimed for use the treatment of disorders, such as Conn's Syndrome, primary and secondary hyperaldosteronism, increased sodium retention, increased magnesium and potassium excretion (diuresis), increased water retention, hypertension (isolated systolic and combined systolic/diastolic), arrhythmias, myocardial fibrosis, myocardial infarction, Bartter's Syndrome, disorders associated with excess catecholamine levels, diastolic and systolic. congestive heart failure (CHF), psychoses, cognitive disorders, memory disturbances, depression, bipolar disorder, anxiety disorders, personality disorders, breast cancer, peripheral vascular disease, diabetic nephropathy, cirrhosis with edema and ascites, esophageal varicies, Addison's Disease, muscle weakness, increased melan in pigmentation of the skin, weight loss, hypotension, hypoglycemia, Cushing's Syndrome, obesity, hypertension, glucose intolerance, hyperglycemia, diabetes mellitus, osteoporosis, polyuria, polydipsia, inflammation, rheumatoid arthritis, asthma, or chronic obstructive pulmonary disease,. Diastolic or systolic congestive heart failure, autoimmune disorders, tissue rejection associated with organ transplant, malignancies such as leukemias and lymphomas, acute adrenal insufficiency, congenital adrenal hyperplasia, rheumatic fever, polyarteritis nodosa, granulomatous polyarteritis, inhibition of myeloid cell lines, immune proliferation/apoptosis, HPA axis suppression and regulation, hypercortisolemia, modulation of the Th1/Th2 cytokine balance, chronic kidney disease, stroke and spinal cord injury, hypercalcemia, hypergylcemia, acute adrenal insufficiency, chronic primary adrenal insufficiency, secondary adrenal insufficiency, congenital adrenal hyperplasia, cerebral edema, thrombocytopenia, and Little's syndrome, systemic inflammation, inflammatory bowel disease, systemic lupus erythematosus, discoid lupus erythematosus, polyartitis nodosa, Wegener's granulomatosis, giant cell arthritis, rheumatoid arthritis, osteoarthritis, hay fever, allergic rhinitis, contact dermatitis, atopic dermatitis, exfoliative dermatitis, urticaria, angioneurotic edema, chronic obstructive pulmonary disease, asthma, tendonitis,. Bursitis, Crohn's disease, ulcerative colitis, autoimmune chronic active hepatitis, hepatitis, cirrhosis, inflammatory scalp alopecia, panniculitis, psoriasis, inflamed cysts, pyoderma gangrenosum, pemphigus vulgaris, bullous pemphigoid, dermatomyositis, eosinophilic fasciitis, relapsing polychondritis, inflammatory vasculitis, sarcoidosis, Sweet's disease, type 1 reactive leprosy, capillary hemangiomas, lichen planus,, erythema nodosum, acne, hirsutism, toxic epidermal necrolysis, erythema multiform, cutaneous T-cell lymphoma, emphysema, Alzheimer's Disease, and multipie sclerosis. Thus, dibenzosuberone deriv. II (R = NHMe) was prepd. with 48% yield via reaction of the corresponding sulfonyl chloride II (R = Cl) with MeNH2 in THF. The prepd. dibenzosuberone derivs. and analogs were assayed for mineralocorticoid and glucocorticoid receptor binding.

IT 710341-98-3P 710344-04-0P 710344-05-1P
710344-06-2P 710344-13-1P 710344-14-2P
710344-17-5P 710344-18-6P 710344-19-7P
710344-20-0P 710344-21-1P 710344-24-4P
710344-26-6P 710344-27-7P 710344-28-8P
710344-29-9P 710344-30-2P 710344-31-3P
710344-35-7P 710344-37-9P 710344-38-0P
710345-76-9P 710345-77-0P 710345-78-1P
710345-79-2P 710345-80-5P 710345-81-6P
710345-82-7P 710345-83-8P 710345-84-9P
710345-85-0P 710345-93-0P 710346-00-2P
710346-01-3P 710346-04-6P 710346-06-8P
710346-07-9P 710346-08-0P 710346-09-1P
710346-10-4P 710346-11-5P 710346-12-6P
710346-63-7P 710346-64-8P 710346-65-9P
710346-66-0P 710346-67-1P 710346-68-2P
710346-69-3P 710347-80-1P 710347-81-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of derivs. and heterocyclic analogs of dibenzosuberone for use in pharmaceutical compns. as steroid hormone nuclear receptor modulators)

RN 710341-98-3 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710344-04-0 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 710344-05-1 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710344-06-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)



RN 710344-13-1 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(2-fluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 710344-14-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(Z)-(2-fluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 710344-17-5 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(Z)-[2-(difluoromethyl)-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene]methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 710344-18-6 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-[2-(difluoromethyl)-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene]methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 710344-19-7 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-methyl- (CA INDEX NAME)



RN 710344-20-0 CAPLUS
CN 5H-Dibenzo[a,d]cycloheptene-2-carbonitrile, 5-[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)methylene]-10,11-dihydro-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 710344-21-1 CAPLUS
CN 5H-Dibenzo[a,d]cycloheptene-2-carbonitrile, 5-[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)methylene]-10,11-dihydro-, (5E)- (CA INDEX NAME)

RN 710344-27-7 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(2-fluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-methyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 710344-28-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,4-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710344-29-9 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-(1-methylethyl)- (CA INDEX NAME)



RN 710344-30-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(Z)-(4-chloro-10,11-dihydro-5H-

Double bond geometry as shown.



RN 710344-24-4 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-methyl- (CA INDEX NAME)



RN 710344-26-6 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(Z)-(2-fluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-methyl- (CA INDEX NAME)

Double bond geometry as shown.



dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 710344-31-3 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(4-chloro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 710344-35-7 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(1,9-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710344-37-9 CAPLUS

CN 2H-Benzimidazol-2-one, 5-[(E)-[10,11-dihydro-2-(trifluoromethyl)-5H-dibenzo[a,d]cycloheptен-5-ylidene]methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 710344-38-0 CAPLUS

CN 2H-Benzimidazol-2-one, 5-[(Z)-[10,11-dihydro-2-(trifluoromethyl)-5H-dibenzo[a,d]cycloheptен-5-ylidene]methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 710345-76-9 CAPLUS

CN 2H-Benzimidazol-2-one, 5-[(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 710345-77-0 CAPLUS

CN 2H-Benzimidazol-2-one, 5-[(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)



RN 710345-81-6 CAPLUS

CN 2H-Benzimidazol-2-one, 5-[(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710345-82-7 CAPLUS

CN 2H-Benzimidazol-2-one, 5-[(3-chlorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710345-83-8 CAPLUS

CN 2H-Benzimidazol-2-one, 5-[(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 710345-78-1 CAPLUS

CN 2H-Benzimidazol-2-one, 1-cyclopropyl-5-[(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710345-79-2 CAPLUS

CN 2H-Benzimidazol-2-one, 5-[(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710345-80-5 CAPLUS

CN 2H-Benzimidazol-2-one, 5-[(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(1-methylethyl)- (CA INDEX NAME)



RN 710345-84-9 CAPLUS

CN 2H-Benzimidazol-2-one, 5-[(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710345-85-0 CAPLUS

CN 2H-Benzimidazol-2-one, 5-[(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 710345-93-0 CAPLUS

CN 2H-Benzimidazol-2-one, 5-(dibenz[b,e]oxepin-11(6H)-ylidenemethyl)-1,3-dihydro- (CA INDEX NAME)



RN 710346-00-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(Z)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-methyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 710346-01-3 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-methyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 710346-04-6 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[(3-methoxydibenz[b,e]oxepin-11(6H)-ylidene)methyl]- (CA INDEX NAME)



RN 710346-06-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(8-chlorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710346-07-9 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(4-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710346-08-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[[3-(trifluoromethyl)dibenz[b,e]oxepin-11(6H)-ylidene]methyl]- (CA INDEX NAME)



RN 710346-09-1 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(3-fluoro-6,11-dihydrodibenz[b,e]oxepin-11-yl)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710346-10-4 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 710346-11-5 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(3-chlorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 710346-12-6 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 710346-63-7 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(2-methylpropyl)- (CA INDEX NAME)

Double bond geometry as shown.



RN 710346-64-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(Z)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(2-methylpropyl)- (CA INDEX NAME)

Double bond geometry as shown.



RN 710346-65-9 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(7-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710346-66-0 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(9-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710346-67-1 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(9-chlorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 710347-81-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(5Z)-1-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)ethyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



RN 710346-68-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(Z)-(9-chlorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 710346-69-3 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1,3-dimethyl- (CA INDEX NAME)



RN 710347-80-1 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(5E)-1-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)ethyl]-1,3-dihydro- (CA INDEX NAME)

L10 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:933397 CAPLUS
DOCUMENT NUMBER: 124:202102
ORIGINAL REFERENCE NO.: 124:37365a,37368a
TITLE: Improved synthesis of thromboxane A2 receptor antagonists with a dibenzoxepin ring system
AUTHOR(S): Sugaya, Toru; Kato, Nobuyuki; Sakaguchi, Akihiko; Tomioka, Shinji
CORPORATE SOURCE: Sakai Res. Laboratories, Kyowa Hakko Kogyo Co., Ltd., Sakai, 590, Japan
SOURCE: Synthesis (1995), (10), 1257-62
CODEN: SYNTBF; ISSN: 0039-7881
PUBLISHER: Thieme
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The nonprostanoid thromboxane A2 (TXA2) receptor antagonists I (R = R1 = Me; R = H, R1 = MeO) were synthesized on the gram scale from the corresponding Me 11-oxodihydrodibenzoxepincarboxylate. The CO group at C(11) was converted via a formylmethylene into a 1-azadiene moiety by reaction with a 2-aminoformanilide derivative Stereo- and regioselective elaboration of the unsym. imidazoles was achieved through a sequence of the transformation of E,Z-1-azadiene intermediates to E isomers under acidic conditions followed by cyclization to imidazoles.

IT 174074-44-3P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of dibenzoxepin derivs. as thromboxane A2 receptor antagonists)

RN 174074-44-3 CAPLUS
CN Dibenz[b,e]oxepin-2-carboxylic acid, 6,11-dihydro-11-[2-(6-methoxy-1H-benzimidazol-1-yl)ethylidene]-, sodium salt, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L10 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L10 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1992:550936 CAPLUS
DOCUMENT NUMBER: 117:150936
ORIGINAL REFERENCE NO.: 117:26149a,26152a
TITLE: Non-prostanoid thromboxane A2 receptor antagonists with a dibenzoxepin ring system. 2
AUTHOR(S): Ohshima, Etsuo; Takami, Hitoshi; Sato, Hideyuki; Mohri, Shinichiro; Obase, Hiroyuki; Miki, Ichiro; Ishii, Akio; Shirakura, Shiro; Karasawa, Akira; Kubo, Kazuhiro
CORPORATE SOURCE: Pharm. Res. Lab., Kyowa Hakko Kogyo Co., Ltd., Nagaizumi, 411, Japan
SOURCE: Journal of Medicinal Chemistry (1992), 35(18), 3402-13
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB A series of 11-[2-(1-benzimidazolyl)ethylidene]-6,11-dihydrodibenz[b,e]oxepin-2-carboxylic acid derivs. and related compds. were synthesized and found to be potent TXA2/PGH2 receptor antagonists. Each compound synthesized was tested for its ability to displace [3H]U-46619 binding from guinea pig platelet TXA2/PGH2 receptors. Structure-activity relationship studies revealed that the following key elements were required for enhanced activities: (1) an (E)-2-(1-benzimidazolyl)ethylidene side chain in the 11-position of the dibenzoxepin ring system and (2) a carboxyl group in the 2-position of the dibenzoxepin ring system. The studies also indicated that the TXA2/PGH2 receptor binding affinities of this series of compds. in guinea pig platelet were poorly correlated with those in human platelet. Introduction of substituent(s) to the benzimidazole moiety was effective and sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)ethylidene]-6,11-dihydrodibenz[b,e]oxepin-2-carboxylate monohydrate (I) recorded the highest affinity for human platelet TXA2PGH2 receptor with a Ki value of 1.2 ± 0.14 nM. It demonstrated potent inhibitory effects on U-46619-induced guinea pig platelet aggregation (in vitro and ex vivo) and human platelet aggregation (in vitro). Compound I is a novel, orally active, and specific TXA2/PGH2 receptor antagonist with neither TXA2/PGH2 receptor agonistic nor TXA2 synthase inhibitory effects.

IT 127165-73-5P 127165-94-0P 127165-96-2P
127167-37-7P 142535-80-6P 142535-85-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

L10 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 127165-73-5 CAPLUS
CN Dibenz[b,e]oxepin-2-carboxylic acid, 6,11-dihydro-11-[2-(5-methoxy-1H-benzimidazol-1-yl)ethylidene]-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 127165-94-0 CAPLUS
CN Dibenz[b,e]oxepin-2-carboxylic acid, 11-[2-(5,7-dimethoxy-1H-benzimidazol-1-yl)ethylidene]-6,11-dihydro-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 127165-96-2 CAPLUS
CN Dibenz[b,e]oxepin-2-carboxylic acid, 11-[2-(5,6-dimethoxy-1H-benzimidazol-1-yl)ethylidene]-6,11-dihydro-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 127167-37-7 CAPLUS
CN Dibenz[b,e]oxepin-2-carboxylic acid, 11-[2-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)ethylidene]-6,11-dihydro-, methyl ester, (E)- (9CI) (CA INDEX NAME)

L10 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Double bond geometry as shown.



RN 142535-80-6 CAPLUS
CN Dibenz[b,e]oxepin-2-carboxylic acid, 6,11-dihydro-11-[2-(4-hydroxy-1H-benzimidazol-1-yl)ethylidene]-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 142535-85-1 CAPLUS
CN Dibenz[b,e]oxepin-2-carboxylic acid, 11-[2-(4,7-dimethoxy-1H-benzimidazol-1-yl)ethylidene]-6,11-dihydro-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 127165-74-6P 127166-32-9P 127166-34-1P
127166-49-8P 127166-50-1P 127166-51-2P
127167-43-5P 142535-63-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as thromboxane receptor antagonist)

L10 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 127165-74-6 CAPLUS
CN Dibenz[b,e]oxepin-2-carboxylic acid, 6,11-dihydro-11-[2-(6-methoxy-1H-benzimidazol-1-yl)ethylidene]-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 127166-32-9 CAPLUS
CN Dibenz[b,e]oxepin-2-carboxylic acid, 6,11-dihydro-11-[2-(5-methoxy-1H-benzimidazol-1-yl)ethylidene]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 127166-34-1 CAPLUS
CN Dibenz[b,e]oxepin-2-carboxylic acid, 6,11-dihydro-11-[2-(6-methoxy-1H-benzimidazol-1-yl)ethylidene]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 127166-49-8 CAPLUS
CN Dibenz[b,e]oxepin-2-carboxylic acid, 11-[2-(5,6-dimethoxy-1H-benzimidazol-1-yl)ethylidene]-6,11-dihydro-, (E)- (9CI) (CA INDEX NAME)

L10 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 142535-63-5 CAPLUS
CN Dibenz[b,e]oxepin-2-carboxylic acid, 6,11-dihydro-11-[2-(4-hydroxy-1H-benzimidazol-1-yl)ethylidene]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L10 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
Double bond geometry as shown.



RN 127166-50-1 CAPLUS
CN Dibenz[b,e]oxepin-2-carboxylic acid, 11-[2-(4,6-dimethoxy-1H-benzimidazol-1-yl)ethylidene]-6,11-dihydro-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 127166-51-2 CAPLUS
CN Dibenz[b,e]oxepin-2-carboxylic acid, 11-[2-(5,7-dimethoxy-1H-benzimidazol-1-yl)ethylidene]-6,11-dihydro-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 127167-43-5 CAPLUS
CN Dibenz[b,e]oxepin-2-carboxylic acid, 11-[2-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)ethylidene]-6,11-dihydro-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L10 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1991:122177 CAPLUS
DOCUMENT NUMBER: 114:122177
ORIGINAL REFERENCE NO.: 114:20809a,20812a
TITLE: Stereoselective synthesis of novel thromboxane A2 receptor antagonists via stereoselective 1-azadiene isomerization
AUTHOR(S): Sugaya, Toru; Kato, Nobuyuki; Tomioka, Shinji; Tamaki, Kentaro
CORPORATE SOURCE: Sakai Res. Lab., Kyowa Hakko Kogyo Co., Ltd., Sakai, 590, Japan
SOURCE: Chemistry Letters (1990), (12), 2181-2
CODEN: CMLTAG; ISSN: 0366-7022
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 114:122177
GI



I



II

AB Novel non-prostanoid thromboxane A2 receptor antagonists I (R = R1 = Me; R
= H, R1 = OMe) were synthesized stereoselectively using the transformation
of (E,Z)-1-azadiene intermediates II to only the E-isomers under acidic conditions.
IT 127165-74-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and ester hydrolysis of)

L10 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 127165-74-6 CAPLUS
CN Dibenz[b,e]oxepin-2-carboxylic acid,
6,11-dihydro-11-[2-(6-methoxy-1H-benzimidazol-1-yl)ethylidene]-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 132382-49-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(stereoselective preparation of)
RN 132382-49-1 CAPLUS
CN Dibenz[b,e]oxepin-2-carboxylic acid,
6,11-dihydro-11-[2-(6-methoxy-1H-benzimidazol-1-yl)ethylidene]-, methyl ester (CA INDEX NAME)



L10 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN Dibenz[b,e]oxepin-2-carboxylic acid,
6,11-dihydro-11-[2-(6-methoxy-1H-benzimidazol-1-yl)ethylidene]-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L10 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1991:122085 CAPLUS
DOCUMENT NUMBER: 114:122085
ORIGINAL REFERENCE NO.: 114:20792h,20793a
TITLE: Preparation of dibenzoxepin derivatives as intermediates for thromboxane A2 (TXA2) inhibitors
INVENTOR(S): Sugaya, Toru; Kato, Nobuyuki; Tomioka, Shinji; Tamaoki, Kentaro
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02233676	A	19900917	JP 1989-53378	19890306
JP 2877333	B2	19990331		
PRIORITY APPLN. INFO.:			JP 1989-53378	19890306

OTHER SOURCE(S): MARPAT 114:122085
GI



I II

AB The title compds. I [A = (CH2)nCO2R2; R1, R2 = H, lower alkyl; X1 - X3 = H, OH, halo, lower alkyl or alkoxy; n = 0-4], are prepared as intermediates for TXA2 inhibitors dibenzoxepins II (A, R1, R2, X1 - X3, n = same as I). Isomeric mixts. or Z-isomers of I are converted to the corresponding E-isomers by acid treatment. Thus, Me 11-methylidene-6,11-dihydrodibenz[b,e]oxepin-2-carboxylate was treated with POCl3 and PhNMeCHO to give 86% (E,Z)-Me 11-formylmethylidene-6,11-dihydrodibenz[b,e]oxepin-2-carboxylate which was was refluxed 1 h with 2-formylamino-5-methoxyaniline in CH2Cl2 and treated with MeSO3H at 70° for 1 h gave 86.5% (E)-I (A = 2-CO2Me, R1 = X1 = X2 = H, X3 = 5-OMe) (III). Then, reduction of III with NaBH4 followed by cyclization with HCO2H gave 71.4% (E)-II (A = 2-CO2Me, R1 = X1 = X2 = H, X3 = 6-OMe).
IT 127165-74-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as TXA2 inhibitor)
RN 127165-74-6 CAPLUS

L10 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1990:235301 CAPLUS
DOCUMENT NUMBER: 112:235301
ORIGINAL REFERENCE NO.: 112:39693a,39696a
TITLE: Preparation and formulation of heterocycle-containing dibenzoxepin, dibenzocycloheptene, and dibenzothiepin derivatives as TXA2 antagonists
INVENTOR(S): Oshima, Etsuo; Obase, Hiroyuki; Karasawa, Akira; Kubo, Kazuhiro; Miki, Ichiro; Ishii, Akio
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 169 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 345747	A2	19891213	EP 1989-110272	19890607
EP 345747	A3	19900704		
EP 345747	B1	19960626		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 4999363	A	19910312	US 1989-368242	19890606
CA 1338625	C	19961001	CA 1989-601928	19890606
AT 139776	T	19960715	AT 1989-110272	19890607
ES 2091190	T3	19961101	ES 1989-110272	19890607
JP 02091040	A	19900330	JP 1989-146049	19890608
JP 07037416	B	19950426		
US 5118701	A	19920602	US 1990-612446	19901114
US 5242931	A	19930907	US 1992-856296	19920323
US 5302596	A	19940412	US 1992-980617	19921123
PRIORITY APPLN. INFO.:			JP 1988-142374 A	19880609
			US 1989-368242 A3	19890606
			US 1990-612446 A3	19901114
			US 1992-856296 A3	19920323

OTHER SOURCE(S): MARPAT 112:235301
GI



I



II



III

AB The title compds. [I; X1-X2 = CH2O, CH2S, CH2CH2, CH:CH; G1, G2 = alkyl, halo, OH, alkoxy; a, b = 0-3; one of R1 and R2 = H, and the other = CO2H, alkoxycarbonyl, (un)substituted ω-carboxyalkyl or -1-alkenyl; W1 = S, SO2, O, NH, alkylimino, NHCO, N, CH, CH2; n = 0-4; W2 = bond, S, NH, alkylimino; Z = (hetero)aryl], having a TXA2 biosynthesis inhibiting activity and/or a TXA2 receptor antagonizing activity and useful for treatment of ischemic, cerebro-vascular, inflammatory, or allergic diseases, etc., are prepared Thus, chlorination of Et 11-hydroxy-6,11-dihydrodibenz[b,c]oxepin-2-carboxylate with SOCl2 in CH2Cl2 and amination of the resulting 11-chloro derivative with 3-(aminomethyl)pyridine in CHCl2 in the presence of N,N-dicyclohexylmethylamine gave a 6,11-dihydrodibenz[b,c]oxepin derivative (II; R = Et). III (R = Me) (IV) at 3 mg/kg body weight in anesthetized rats lowered thrombus formation on cotton thread kept in an extracorporeal circulation path for the left jugular vein from 22.4 mg (control) to 14.2 mg. IV in vitro antagonized 9,11-dideoxy-9α,11a-methanoepoxyprostaglandin F2α-induced guinea pig platelet aggregation with a min. effective concentration of 0.1 μg/mL.

IT 127165-73-5P 127165-74-6P 127165-93-9P
127165-94-0P 127165-96-2P 127166-32-9P
127166-34-1P 127166-49-8P 127166-50-1P
127166-51-2P 127167-34-4P 127167-37-7P
127167-40-2P 127167-43-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as thromboxane A2 antagonist)

RN 127165-73-5 CAPLUS
CN Dibenz[b,e]oxepin-2-carboxylic acid, 6,11-dihydro-11-[2-(5-methoxy-1H-benzimidazol-1-yl)ethylidene]-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 127165-74-6 CAPLUS
CN Dibenz[b,e]oxepin-2-carboxylic acid, 6,11-dihydro-11-[2-(6-methoxy-1H-benzimidazol-1-yl)ethylidene]-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 127165-93-9 CAPLUS
CN Dibenz[b,e]oxepin-2-carboxylic acid, 11-[2-(4,6-dimethoxy-1H-benzimidazol-1-yl)ethylidene]-6,11-dihydro-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 127165-94-0 CAPLUS
CN Dibenz[b,e]oxepin-2-carboxylic acid, 11-[2-(5,7-dimethoxy-1H-benzimidazol-1-yl)ethylidene]-6,11-dihydro-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 127165-96-2 CAPLUS
CN Dibenz[b,e]oxepin-2-carboxylic acid, 11-[2-(5,6-dimethoxy-1H-benzimidazol-1-yl)ethylidene]-6,11-dihydro-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 127166-32-9 CAPLUS
CN Dibenz[b,e]oxepin-2-carboxylic acid, 6,11-dihydro-11-[2-(5-methoxy-1H-benzimidazol-1-yl)ethylidene]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 127166-34-1 CAPLUS
CN Dibenz[b,e]oxepin-2-carboxylic acid, 6,11-dihydro-11-[2-(6-methoxy-1H-benzimidazol-1-yl)ethylidene]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 127166-49-8 CAPLUS
CN Dibenz[b,e]oxepin-2-carboxylic acid, 11-[2-(5,6-dimethoxy-1H-benzimidazol-1-yl)ethylidene]-6,11-dihydro-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 127166-50-1 CAPLUS
CN Dibenz[b,e]oxepin-2-carboxylic acid, 11-[2-(4,6-dimethoxy-1H-benzimidazol-1-yl)ethylidene]-6,11-dihydro-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 127166-51-2 CAPLUS
CN Dibenz[b,e]oxepin-2-carboxylic acid, 11-[2-(5,7-dimethoxy-1H-benzimidazol-1-yl)ethylidene]-6,11-dihydro-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 127167-34-4 CAPLUS
CN Dibenz[b,e]oxepin-2-carboxylic acid,
11-[2-(2,3-dihydro-3-oxo-1H-indazol-1-yl)ethylidene]-6,11-dihydro-,
methyl
ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 127167-37-7 CAPLUS
CN Dibenz[b,e]oxepin-2-carboxylic acid,
11-[2-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)ethylidene]-6,11-dihydro-,
methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 127167-40-2 CAPLUS
CN Dibenz[b,e]oxepin-2-carboxylic acid,
11-[2-(2,3-dihydro-3-oxo-1H-indazol-1-yl)ethylidene]-6,11-dihydro-, (E)-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 127167-43-5 CAPLUS
CN Dibenz[b,e]oxepin-2-carboxylic acid,
11-[2-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)ethylidene]-6,11-dihydro-,
(E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



```
=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    40.48     361.50

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -5.74      -5.74

STN INTERNATIONAL LOGOFF AT 12:11:48 ON 29 MAY 2009
```